ViroGates A/S

ViroGates A/S Liabilities

The The Liabilities of ViroGates A/S (VIRO.CO) as of Nov 22, 2026 is 11.19 M DKK. In the previous year, The Liabilities was 6.87 M DKK — a change of 62.94% (higher).

Liabilities

11.19 MDKK

YoY

62.94%

Last updated:

In 2025, ViroGates A/S's total liabilities amounted to 11.19 M DKK, a 62.94% difference from the 6.87 M DKK total liabilities in the previous year.

The ViroGates A/S Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.41 M DKK
Jan 1, 2019
2.94 M DKK
Jan 1, 2020
6.93 M DKK
Jan 1, 2021
3.80 M DKK
Jan 1, 2022
1.45 M DKK
Jan 1, 2023
7.55 M DKK
Jan 1, 2024
6.87 M DKK
Jan 1, 2025
11.19 M DKK
The ViroGates A/S Liabilities history
YEARLiabilitiesYoY
11.19 MDKK+62.94%
6.87 MDKK-9.05%
7.55 MDKK+420.19%
1.45 MDKK-61.85%
3.80 MDKK-45.14%
6.93 MDKK+135.62%
2.94 MDKK+21.97%
2.41 MDKK+21.76%
1.98 MDKK-34.23%
3.01 MDKK-0.46%
3.03 MDKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing ViroGates A/S's Liabilities

ViroGates A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ViroGates A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ViroGates A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ViroGates A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ViroGates A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ViroGates A/S stock

The Liabilities of ViroGates A/S is 11.19 M DKK in 2025.

The Liabilities of ViroGates A/S changed from 6.87 M DKK to 11.19 M DKK, representing a 62.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's ViroGates A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViroGates A/S

All Key Metrics — ViroGates A/S